dac-30
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2003 (NCT00122564)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3beta-(n-(n',n'-dimethylaminoethane)carbamoyl)cholesterol
- 3-(n-(n',n'-dimethylaminoethane)carbamoyl)cholesterol
- dac 30
- dac-30
- dc-chol
- dc-chol
- dc-chol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00122564 | Phase 1 | Jun 1, 2003 | Aventis, French National Agency for Research on AIDS and Viral Hepatitis, University of Paris |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aventis | For profit | 1 | 0 | 1 | 2003 |
| French National Agency for Research on AIDS and Viral Hepatitis | Government | 1 | 1 | 1 | 2003 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2003 |
3 organizations
Page 1 / 1